Overexpression of IL-18 Decreases Intimal Collagen Content and Promotes a Vulnerable Plaque Phenotype in Apolipoprotein-E–Deficient Mice

DOI Web Site 被引用文献1件
  • R. de Nooijer
    From the Division of Biopharmaceutics (R.d.N., J.H.v.d.T., C.J.N.V., J.K., Th.J.C.v.B., E.A.L.B.) and the Department of Cardiology (R.d.N., J.W.J., E.E.v.d.W.), Leiden University Medical Center, Leiden, the Netherlands.
  • J.H. von der Thüsen
    From the Division of Biopharmaceutics (R.d.N., J.H.v.d.T., C.J.N.V., J.K., Th.J.C.v.B., E.A.L.B.) and the Department of Cardiology (R.d.N., J.W.J., E.E.v.d.W.), Leiden University Medical Center, Leiden, the Netherlands.
  • C.J.N. Verkleij
    From the Division of Biopharmaceutics (R.d.N., J.H.v.d.T., C.J.N.V., J.K., Th.J.C.v.B., E.A.L.B.) and the Department of Cardiology (R.d.N., J.W.J., E.E.v.d.W.), Leiden University Medical Center, Leiden, the Netherlands.
  • J. Kuiper
    From the Division of Biopharmaceutics (R.d.N., J.H.v.d.T., C.J.N.V., J.K., Th.J.C.v.B., E.A.L.B.) and the Department of Cardiology (R.d.N., J.W.J., E.E.v.d.W.), Leiden University Medical Center, Leiden, the Netherlands.
  • J.W. Jukema
    From the Division of Biopharmaceutics (R.d.N., J.H.v.d.T., C.J.N.V., J.K., Th.J.C.v.B., E.A.L.B.) and the Department of Cardiology (R.d.N., J.W.J., E.E.v.d.W.), Leiden University Medical Center, Leiden, the Netherlands.
  • E.E. van der Wall
    From the Division of Biopharmaceutics (R.d.N., J.H.v.d.T., C.J.N.V., J.K., Th.J.C.v.B., E.A.L.B.) and the Department of Cardiology (R.d.N., J.W.J., E.E.v.d.W.), Leiden University Medical Center, Leiden, the Netherlands.
  • Th.J.C. van Berkel
    From the Division of Biopharmaceutics (R.d.N., J.H.v.d.T., C.J.N.V., J.K., Th.J.C.v.B., E.A.L.B.) and the Department of Cardiology (R.d.N., J.W.J., E.E.v.d.W.), Leiden University Medical Center, Leiden, the Netherlands.
  • E.A.L. Biessen
    From the Division of Biopharmaceutics (R.d.N., J.H.v.d.T., C.J.N.V., J.K., Th.J.C.v.B., E.A.L.B.) and the Department of Cardiology (R.d.N., J.W.J., E.E.v.d.W.), Leiden University Medical Center, Leiden, the Netherlands.

説明

<jats:p> <jats:bold> <jats:italic>Objective—</jats:italic> </jats:bold> Although IL-18 has been implicated in atherosclerotic lesion development, little is known about its role in advanced atherosclerotic plaques. This study aims to assess the effect of IL-18 overexpression on the stability of preexisting plaques. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> Atherosclerotic lesions were elicited in carotid arteries of apolipoprotein E (apoE)-deficient mice (n=32) by placement of a perivascular collar. Overexpression of IL-18 was effected by intravenous injection of an adenoviral vector 5 weeks after surgery. Two weeks after transduction, lesions were analyzed histologically with regard to plaque morphology and composition or by real-time polymerase chain reaction. No difference in plaque size was detected between groups. In the Ad.IL-18–treated group, 62% of lesions displayed a vulnerable morphology or even intraplaque hemorrhage as compared with only 24% in the controls ( <jats:italic>P</jats:italic> =0.037). In agreement, IL-18 overexpression reduced intimal collagen by 44% ( <jats:italic>P</jats:italic> <0.003) and cap-to-core ratio by 41% ( <jats:italic>P</jats:italic> <0.002). Although IL-18 did not affect the expression of collagen synthesis-related genes, it was found to enhance the collagenolytic activity of vascular smooth muscle cells in vitro, suggesting that the low collagen content is attributable to matrix degradation rather than to decreased synthesis. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusion—</jats:italic> </jats:bold> Systemic IL-18 overexpression markedly decreases intimal collagen content and cap thickness, leading to a vulnerable plaque morphology. </jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ